Literature DB >> 33340994

Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.

Federico Boiardi1, Justin Stebbing2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33340994      PMCID： PMC7750542          DOI： 10.1016/j.ebiom.2020.103170

Source DB:  PubMed          Journal:  EBioMedicine        ISSN： 2352-3964            Impact factor:   8.143


× No keyword cloud information.
  5 in total

1.  Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice.

Authors:  Amabel C L Tan; Edin J Mifsud; Weiguang Zeng; Kathryn Edenborough; Jodie McVernon; Lorena E Brown; David C Jackson
Journal:  Mol Pharm       Date:  2012-08-03       Impact factor: 4.939

2.  Identification of ferret ACE2 and its receptor function for SARS-coronavirus.

Authors:  Aya Zamoto; Fumihiro Taguchi; Shuetsu Fukushi; Shigeru Morikawa; Yasuko K Yamada
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

3.  Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

Authors:  Pamela C Proud; Daphne Tsitoura; Robert J Watson; Brendon Y Chua; Marilyn J Aram; Kevin R Bewley; Breeze E Cavell; Rebecca Cobb; Stuart Dowall; Susan A Fotheringham; Catherine M K Ho; Vanessa Lucas; Didier Ngabo; Emma Rayner; Kathryn A Ryan; Gillian S Slack; Stephen Thomas; Nadina I Wand; Paul Yeates; Christophe Demaison; Weiguang Zeng; Ian Holmes; David C Jackson; Nathan W Bartlett; Francesca Mercuri; Miles W Carroll
Journal:  EBioMedicine       Date:  2020-12-03       Impact factor: 8.143

4.  The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation.

Authors:  D Tien Nguyen; Lot de Witte; Martin Ludlow; Selma Yüksel; Karl-Heinz Wiesmüller; Teunis B H Geijtenbeek; Albert D M E Osterhaus; Rik L de Swart
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

5.  What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials.

Authors:  Silvia Ottaviani; Justin Stebbing
Journal:  Med (N Y)       Date:  2020-05-19
  5 in total
  1 in total

1.  AYURAKSHA, a prophylactic Ayurvedic immunity boosting kit reducing positivity percentage of IgG COVID-19 among frontline Indian Delhi police personnel: A non-randomized controlled intervention trial.

Authors:  Tanuja Nesari; Sujata Kadam; Mahesh Vyas; Vitthal G Huddar; Pradeep Kumar Prajapati; Manjusha Rajagopala; Anand More; Shri Krishna Rajagopala; Santosh Kumar Bhatted; Rama Kant Yadav; Vyasdeva Mahanta; Sisir Kumar Mandal; Raja Ram Mahto; Divya Kajaria; Rahul Sherkhane; Narayan Bavalatti; Pankaj Kundal; Prasanth Dharmarajan; Meera Bhojani; Bhargav Bhide; Shiva Kumar Harti; Arun Kumar Mahapatra; Umesh Tagade; Galib Ruknuddin; Anandaraman Puthanmadam Venkatramana Sharma; Shalini Rai; Shivani Ghildiyal; Pramod R Yadav; Jonah Sandrepogu; Meena Deogade; Pankaj Pathak; Alka Kapoor; Anil Kumar; Heena Saini; Richa Tripathi
Journal:  Front Public Health       Date:  2022-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.